Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prediction of recurrence and functional status in young ischemic stroke patients: Comparison of machine learning and traditional statistical methods.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026

Same author

Guillain-Barré Syndrome Disability Scale.

Journal of the peripheral nervous system : JPNS·2025

Same author

Unlocking the Future of Alzheimer's Disease: Innovations in Diagnosis and Therapy.

The Journal of the Association of Physicians of India·2025

Same author

Statins in Acute Ischemic Stroke: Mechanisms, Resistance, and Precision Strategies for Neurovascular and Cognitive Protection.

CNS drugs·2025

Same author

Continuing medical education in epileptology: The Level 1-2-3 experience of the ILAE academy.

Epileptic disorders : international epilepsy journal with videotape·2025

Same author

Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage: The Global Burden of Disease Study 2021.

JAMA neurology·2025

Search research articles

Related Experiment Video

Updated: May 19, 2026

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Richard A C Hughes¹, Man Mohan Mehndiratta

¹MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK. rhughes11@btinternet.com.

The Cochrane Database of Systematic Reviews

|August 17, 2012

Summary

Corticosteroids show limited evidence for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). While prednisone did not significantly improve outcomes in one trial, monthly dexamethasone and daily prednisolone showed similar efficacy with fewer side effects for dexamethasone.

Related Experiment Videos

Last Updated: May 19, 2026

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

Area of Science:

Neurology
Immunology

Background:

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disorder causing progressive paralysis.
Corticosteroids are commonly used, with prednisone, prednisolone, and dexamethasone being frequent choices.

Purpose of the Study:

To evaluate corticosteroid efficacy versus placebo for CIDP.
To compare different corticosteroid regimens for CIDP treatment.

Main Methods:

Searched multiple databases (Cochrane, CENTRAL, MEDLINE, EMBASE) for randomized trials of corticosteroids for CIDP.
Included randomized or quasi-randomized trials using internationally accepted CIDP diagnostic criteria.
Extracted data on disability, impairment, nerve conduction, and adverse events.

Main Results:

One trial showed a non-significant improvement in neuropathy impairment scores with prednisone versus no treatment (RR 2.02).
A second trial found no significant difference in remission or disability between daily prednisolone and monthly dexamethasone.
Monthly dexamethasone was associated with significantly fewer instances of sleeplessness and moon facies compared to daily prednisolone.

Conclusions:

Very low-quality evidence suggests prednisone may not offer statistically significant benefits over no treatment for CIDP.
Moderate-quality evidence indicates similar efficacy between daily prednisolone and monthly high-dose dexamethasone.
Further research is needed to identify predictors of corticosteroid response in CIDP.